O	0	4	Role
O	5	7	of
O	8	16	axillary
O	17	26	clearance
O	27	32	after
O	33	34	a
O	35	40	tumor
O	40	41	-
O	41	49	positive
O	50	58	sentinel
O	59	63	node
O	64	66	in
O	67	70	the
O	71	85	administration
O	86	88	of
O	89	97	adjuvant
O	98	105	therapy
O	106	108	in
O	109	114	early
O	115	121	breast
O	122	128	cancer
O	128	129	.

O	130	137	PURPOSE
O	138	141	The
O	142	147	After
O	148	155	Mapping
O	156	158	of
O	159	162	the
O	163	169	Axilla
O	169	170	:
O	171	183	Radiotherapy
O	184	186	or
O	187	194	Surgery
O	194	195	?

O	196	197	(
O	197	203	AMAROS
O	203	204	)
O	205	210	phase
O	211	214	III
O	215	220	study
O	221	229	compares
B-intervention	230	238	axillary
I-intervention	239	244	lymph
I-intervention	245	249	node
I-intervention	250	260	dissection
I-intervention	261	262	(
I-intervention	262	266	ALND
I-intervention	266	267	)
O	268	271	and
B-control	272	280	axillary
I-control	281	290	radiation
I-control	291	298	therapy
I-control	299	300	(
I-control	300	303	ART
I-control	303	304	)
O	305	307	in
B-eligibility	308	313	early
I-eligibility	314	320	breast
I-eligibility	321	327	cancer
I-eligibility	328	336	patients
I-eligibility	337	341	with
I-eligibility	342	347	tumor
I-eligibility	347	348	-
I-eligibility	348	356	positive
I-eligibility	357	365	sentinel
I-eligibility	366	371	nodes
O	371	372	.

O	373	375	In
O	376	379	the
O	380	383	ART
O	384	387	arm
O	387	388	,
O	389	392	the
O	393	399	extent
O	400	402	of
O	403	408	nodal
O	409	420	involvement
O	421	428	remains
O	429	436	unknown
O	436	437	,
O	438	443	which
O	444	449	could
O	450	454	have
O	455	467	implications
O	468	470	on
O	471	474	the
O	475	489	administration
O	490	492	of
O	493	501	adjuvant
O	502	509	therapy
O	509	510	.

O	511	513	In
O	514	518	this
O	519	530	preliminary
O	531	539	analysis
O	539	540	,
O	541	543	we
O	544	551	studied
O	552	555	the
O	556	565	influence
O	566	568	of
O	569	575	random
O	576	586	assignment
O	587	589	to
O	590	594	ALND
O	595	597	or
O	598	601	ART
O	602	604	on
O	605	608	the
O	609	615	choice
O	616	619	for
O	620	628	adjuvant
O	629	638	treatment
O	638	639	.

O	640	648	PATIENTS
O	649	652	AND
O	653	660	METHODS
O	661	663	In
O	664	667	the
O	668	673	first
B-total-participants	674	675	2
I-total-participants	675	676	,
I-total-participants	676	679	000
O	680	688	patients
O	689	697	enrolled
O	698	700	in
O	701	704	the
O	705	711	AMAROS
O	712	717	trial
O	717	718	,
O	719	721	we
O	722	730	analyzed
O	731	734	the
O	735	749	administration
O	750	752	of
O	753	761	adjuvant
O	762	770	systemic
O	771	778	therapy
O	778	779	.

O	780	792	Multivariate
O	793	801	analysis
O	802	805	was
O	806	810	used
O	811	813	to
O	814	820	assess
O	821	830	variables
O	831	840	affecting
O	841	844	the
O	845	859	administration
O	860	862	of
O	863	871	adjuvant
O	872	884	chemotherapy
O	884	885	.

O	886	894	Adjuvant
O	895	902	therapy
O	903	906	was
O	907	914	applied
O	915	924	according
O	925	927	to
O	928	941	institutional
O	942	952	guidelines
O	952	953	.

O	954	961	Results
O	962	964	Of
B-total-participants	965	966	2
I-total-participants	966	967	,
I-total-participants	967	970	000
O	971	979	patients
O	979	980	,
O	981	984	566
O	985	993	patients
O	994	997	had
O	998	999	a
O	1000	1008	positive
O	1009	1017	sentinel
O	1018	1022	node
O	1023	1026	and
O	1027	1031	were
O	1032	1039	treated
O	1040	1043	per
O	1044	1050	random
O	1051	1061	assignment
O	1061	1062	.

O	1063	1068	There
O	1069	1072	was
O	1073	1075	no
O	1076	1087	significant
O	1088	1098	difference
O	1099	1101	in
O	1102	1105	the
O	1106	1120	administration
O	1121	1123	of
O	1124	1132	adjuvant
O	1133	1141	systemic
O	1142	1149	therapy
O	1149	1150	.

O	1151	1153	In
O	1154	1157	the
O	1158	1162	ALND
O	1163	1166	and
O	1167	1170	ART
O	1171	1175	arms
O	1175	1176	,
B-iv-bin-percent	1177	1179	58
I-iv-bin-percent	1179	1180	%
O	1181	1182	(
B-iv-bin-abs	1182	1185	175
O	1186	1188	of
B-intervention-participants	1189	1192	300
O	1192	1193	)
O	1194	1197	and
B-cv-bin-percent	1198	1200	61
I-cv-bin-percent	1200	1201	%
O	1202	1203	(
B-cv-bin-abs	1203	1206	162
O	1207	1209	of
B-control-participants	1210	1213	266
O	1213	1214	)
O	1215	1217	of
O	1218	1221	the
O	1222	1230	patients
O	1230	1231	,
O	1232	1244	respectively
O	1244	1245	,
B-outcome	1246	1254	received
I-outcome	1255	1267	chemotherapy
O	1267	1268	.

B-outcome	1269	1278	Endocrine
I-outcome	1279	1286	therapy
O	1287	1290	was
O	1291	1303	administered
O	1304	1306	in
B-iv-bin-percent	1307	1309	78
I-iv-bin-percent	1309	1310	%
O	1311	1312	(
B-iv-bin-abs	1312	1315	235
O	1316	1318	of
B-intervention-participants	1319	1322	300
O	1322	1323	)
O	1324	1326	of
O	1327	1330	the
O	1331	1339	patients
O	1340	1342	in
O	1343	1346	the
O	1347	1351	ALND
O	1352	1355	arm
O	1356	1359	and
O	1360	1362	in
B-cv-bin-percent	1363	1365	76
I-cv-bin-percent	1365	1366	%
O	1367	1368	(
B-cv-bin-abs	1368	1371	203
O	1372	1374	of
B-control-participants	1375	1378	266
O	1378	1379	)
O	1380	1382	of
O	1383	1386	the
O	1387	1395	patients
O	1396	1398	in
O	1399	1402	the
O	1403	1406	ART
O	1407	1410	arm
O	1410	1411	.

O	1412	1421	Treatment
O	1422	1425	arm
O	1426	1429	was
O	1430	1433	not
O	1434	1435	a
O	1436	1447	significant
O	1448	1454	factor
O	1455	1457	in
O	1458	1461	the
O	1462	1470	decision
O	1470	1471	,
O	1472	1475	and
O	1476	1478	no
O	1479	1491	interactions
O	1492	1499	between
O	1500	1509	treatment
O	1510	1513	arm
O	1514	1517	and
O	1518	1523	other
O	1524	1531	factors
O	1532	1536	were
O	1537	1545	observed
O	1545	1546	.

O	1547	1559	Multivariate
O	1560	1568	analysis
O	1569	1575	showed
O	1576	1580	that
O	1581	1584	age
O	1584	1585	,
O	1586	1591	tumor
O	1592	1597	grade
O	1597	1598	,
O	1599	1612	multifocality
O	1612	1613	,
O	1614	1617	and
O	1618	1622	size
O	1623	1625	of
O	1626	1629	the
O	1630	1638	sentinel
O	1639	1643	node
O	1644	1654	metastasis
O	1655	1668	significantly
O	1669	1677	affected
O	1678	1681	the
O	1682	1696	administration
O	1697	1699	of
O	1700	1712	chemotherapy
O	1712	1713	.

O	1714	1720	Within
O	1721	1724	the
O	1725	1729	ALND
O	1730	1733	arm
O	1733	1734	,
O	1735	1738	the
O	1739	1745	extent
O	1746	1748	of
O	1749	1754	nodal
O	1755	1766	involvement
O	1767	1775	remained
O	1776	1779	not
O	1780	1791	significant
O	1792	1794	in
O	1795	1796	a
O	1797	1808	sensitivity
O	1809	1821	multivariate
O	1822	1830	analysis
O	1830	1831	.

O	1832	1842	CONCLUSION
O	1843	1850	Absence
O	1851	1853	of
O	1854	1863	knowledge
O	1864	1873	regarding
O	1874	1877	the
O	1878	1884	extent
O	1885	1887	of
O	1888	1893	nodal
O	1894	1905	involvement
O	1906	1908	in
O	1909	1912	the
O	1913	1916	ART
O	1917	1920	arm
O	1921	1928	appears
O	1929	1931	to
O	1932	1936	have
O	1937	1939	no
O	1940	1945	major
O	1946	1952	impact
O	1953	1955	on
O	1956	1959	the
O	1960	1974	administration
O	1975	1977	of
O	1978	1986	adjuvant
O	1987	1994	therapy
O	1994	1995	.
